CASE HUB ARCHIVED–this archived case hub reflects the position at the date of the decision to accept commitments on 10 February 2021; it is no longer maintained. See further, timeline and commentary. Case facts Outline European Commission Article 102 TFEU investigation into Aspen concerning whether it has been abusing its dominant position in numerous national markets by charging excessive prices in relation to the supply of off-patient cancer medicines (AT.40394). Latest development On 10 February 2021, the Commission accepted commitments from Aspen, and therefore closed its investigation. Under the commitments accepted: • Aspen will reduce its prices across Europe for the six cancer medicines by, on average, approximately 73% (which is, on average, below the prices charged in 2012, ie before Aspen started increasing its prices) • these prices will be the maximum that Aspen can charge for the coming ten years and will have started taking effect already as of October 2019, and• Aspen guarantees the supply of the medicines for the next five years, and, for an additional five-year period will either continue to supply or make